Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | FASN | P49327 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4165758 | 1.00 | PPARG (0.46) | PPARGGPR132FFAR1FFAR4ALDH1A1 | |
| SCHEMBL28675282 | 1.00 | PPARG (0.46) | PPARGGPR132FFAR1FFAR4ALDH1A1 | |
| SCHEMBL4171793 | 1.00 | PPARG (0.46) | PPARGGPR132FFAR1FFAR4ALDH1A1 | |
| SCHEMBL30570814 | 0.97 | PPARG (0.49) | PPARGGPR132FFAR1FFAR4ALDH1A1 | |
| SCHEMBL7169207 | 0.97 | PPARG (0.49) | PPARGGPR132FFAR1FFAR4ALDH1A1 | |
| SCHEMBL27503948 | 0.97 | PPARG (0.49) | PPARGGPR132FFAR1FFAR4ALDH1A1 | |
| SCHEMBL7169202 | 0.97 | PPARG (0.49) | PPARGGPR132FFAR1FFAR4ALDH1A1 | |
| SCHEMBL7169204 | 0.97 | PPARG (0.49) | PPARGGPR132FFAR1FFAR4ALDH1A1 | |
| SCHEMBL30477427 | 0.97 | PPARG (0.49) | PPARGGPR132FFAR1FFAR4ALDH1A1 | |
| SCHEMBL31059249 | 0.93 | PPARG (0.42) | PPARGGPR132FFAR1FFAR4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9364454-B2 | Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20130150446-A1 | ANTI-INFLAMMATORY ACTIONS OF NEUROPROTECTIN D1/PROTECTIN D1 AND ITS NATURAL STEREOISOMERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-06-13 | — | — | US | disclosed |
| US-8273792-B2 | Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-20090156673-A1 | ANTI-INFLAMMATORY ACTIONS OF NEUROPROTECTIN D1/PROTECTIN D1 AND IT'S NATURAL STEREOISOMERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. CORPORATE SPONSORED RESEARCH & LICENSING (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2007041440-A2 | ANTI-INFLAMMATORY ACTIONS OF NEUROPROTECTIN D1/PROTECTIN D1 AND ITS NATURAL STEREOISOMERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150446-A1 | ANTI-INFLAMMATORY ACTIONS OF NEUROPROTECTIN D1/PROTECTIN D1 AND ITS NATURAL STEREOISOMERS | PTGER1, PTGES, PTGS1 | PPARG 346/4885GPR132 617/4885FFAR1 78/4885 |
| US-20090156673-A1 | ANTI-INFLAMMATORY ACTIONS OF NEUROPROTECTIN D1/PROTECTIN D1 AND IT'S NATURAL STEREOISOMERS | ALOX15, ALOX12, ALOX15B | PPARG 197/4885GPR132 962/4885FFAR1 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.